CRISPR Therapeutics said CASGEVY launch momentum is building and multiple pipeline assets could generate data in the next 12 to 18 months. The company also highlighted zugo-cel progress in oncology and autoimmune disease.
Vie Ventures, a life sciences venture capital firm focused on autoimmune and immune-mediated diseases, announced that Jeff Bluestone, PhD, has been named Managing Director, joining founders Steven St. Peter, MD, and Luke Evnin, PhD.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07661836 |
Personalized Online Occupational Therapy Intervention for Adults With Scleroderma |
ACTIVE_NOT_RECRUITING | NA |
| NCT07641634 |
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. |
RECRUITING | PHASE1/PHASE2 |
| NCT06991114 |
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. |
RECRUITING | PHASE2 |
| NCT06843239 |
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06801119 |
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs） |
RECRUITING | PHASE1 |
| NCT06646913 |
TENS in Scleroderma |
COMPLETED | NA |
| NCT06328777 |
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis |
RECRUITING | PHASE2/PHASE3 |
| NCT06195072 |
Platform Clinical Study for Conquering Scleroderma |
RECRUITING | PHASE2 |
| NCT05925803 |
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05098704 |
Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk |
RECRUITING | PHASE2/PHASE3 |
